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Abstract
Background: The complement component C3a induces degranulation in human mast cells via the activation of cell surface
G protein coupled receptors (GPCR; C3aR). For most GPCRs, agonist-induced receptor phosphorylation leads to the
recruitment of b-arrestin-1/b-arrestin-2; resulting in receptor desensitization and internalization. Activation of GPCRs also
leads to ERK1/2 phosphorylation via two temporally distinct pathways; an early response that reflects G protein activation
and a delayed response that is G protein independent but requires b-arrestins. The role of b-arrestins on C3aR activation/
regulation in human mast cells, however, remains unknown.
Methodology/Principal Findings: We utilized lentivirus short hairpin (sh)RNA to stably knockdown the expression of b-
arrestin-1 and b-arrrestin-2 in human mast cell lines, HMC-1 and LAD2 that endogenously expresses C3aR. Silencing b-
arrestin-2 attenuated C3aR desensitization, blocked agonist-induced receptor internalization and rendered the cells
responsive to C3a for enhanced NF-kB activity as well as chemokine generation. By contrast, silencing b-arrestin-1 had no
effect on these responses but resulted in a significant decrease in C3a-induced mast cell degranulation. In shRNA control
cells, C3a caused a transient ERK1/2 phosphorylation, which peaked at 5 min but disappeared by 10 min. Knockdown of b-
arrestin-1, b-arrestin-2 or both enhanced the early response to C3a and rendered the cells responsive for ERK1/2
phosphorylation at later time points (10–30 min). Treatment of cells with pertussis toxin almost completely blocked both
early and delayed C3a-induced ERK1/2 phosphorylation in b-arrestin1/2 knockdown cells.
Conclusion/Significance: This study demonstrates distinct roles for b-arrestins-1 and b-arrestins-2 on C3aR desensitization,
internalization, degranulation, NF-kB activation and chemokine generation in human mast cells. It also shows that both b-
arrestin-1 and b-arrestin-2 play a novel and shared role in inhibiting G protein-dependent ERK1/2 phosphorylation. These
findings reveal a new level of complexity for C3aR regulation by b-arrestins in human mast cells.
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Introduction
The anaphylatoxin C3a is generated following bacterial
infection and from IgE/FceRI stimulated human mast cells [1].
Accordingly, C3a has been proposed to play critical roles in
innate immunity and allergic diseases such as asthma [2,3,4].
C3a activates its cell surface G protein coupled receptor
(GPCR; C3aR) to induce chemotaxis in human mast cell line
(HMC-1) and degranulation in human skin mast cells,
peripheral blood CD34
+ cell-derived mast cells and a
differentiated mast cell line, LAD2 [1,5,6,7,8]. C3a induces
mast cell degranulation via the activation of phospholipase Cb
and mobilization of intracellular Ca
2+ [7,9]. However, the
mechanism(s) involved in regulation of C3aR signaling in mast
cells remain poorly understood.
It is well established that for most GPCRs, receptor
phosphorylation by G protein coupled receptor kinases (GRKs)
and the subsequent recruitment of b-arrestin provides an
important mechanism for their desensitization and internalization
[10]. Two isoforms of b-arrestins, (b-arrestin-1 and b-arrestin-2)
are known and each can differentially regulate GPCR desensi-
tization and internalization. Thus, for protease activated
receptor-1 (PAR-1) only b-arrestin-1 is capable for receptor
desensitization but receptor internalization is independent of
either b-arrestins [11]. By contrast, both isoforms of b-arrestins
can promote desensitization of b2-adrenergic receptors (bAR2)
and angiotensin II type 1A receptor (AT1AR) [12]. Although,
only b-arrestin-2 promotes internalization of bAR2 both isoforms
are required for the internalization of AT1AR. We have
previously shown that in transfected rat basophilic leukemia
(RBL-2H3) cells, C3aR associates with b-arrestin-2 following
agonist stimulation [9]. However, the roles of b-arrestin-1 and b-
arrestin-2 on C3aR desensitization and internalization have not
been determined.
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phosphorylation-deficient chemoattractant/chemokine receptors
that do not associate with b-arrestins respond to ligands for more
sustained Ca
2+ mobilization and degranulation when compared with
cells expressing wild-type receptors [9,13,14,15,16]. These findings
are consistent with the view that b-arrestins play an important role in
desensitization. By contrast, activation of the chemokine receptor
CXCR1 in human neutrophils leads to receptor internalization and
complex formation between b-arrestin-2 and Src kinases, (Hck and c-
Fgr)whichtranslocatetosecretorygranulestopromotedegranulation
[17]. b-arrestin-2 also forms a complex with Ral-GDP dissociation
stimulator (Ral-GDS) in the cytoplasm of human neutrophils [18].
Furthermore, activation of fMLP receptor results in the translocation
of the complex to the plasma membrane. This is followed by the
releaseofRal-GDSfromb-arrestinand the activation of Ralresulting
in actin cytoskeleton rearrangement presumably leading to degran-
ulation. The roles of b-arrestins on C3a-induced mast cell
degranulation, however, remain unknown.
In addition to receptor desensitization, internalization and degran-
ulation, b-arrestins modulate the activity of the transcription factor,
NF-kB. Witherow et al., [19], using a yeast two-hybrid screen, first
demonstrated that the inhibitor of NF-kB, IkBa binds to b-arrestin-1.
Furthermore, both b-arrestin-1 and 2 interact with IkBa in transfected
cells. However, siRNA-mediated knockdown studies indicated that b-
arrestin-1 but not b-arrestin-2 inhibits TNF-a-induced NF-kB
activation. By contrast, Gao et al., [20] showed that b-arrestin-2, but
not b-arrestin-1 interacts with IkBa to inhibit NF-kBa c t i v a t i o n .
Studies with primary leukocytes from b-arrestin-2 knockout mice
showed that this adapter molecule is involved in the internalization of
the chemokine receptor, CXCR2 [21]. Furthermore, in vivo studies
showed that b-arrestin-2 deletion promotes tumor growth and
angiogenesis and these responses are associated with enhanced
chemokine generation [22]. Other studies have shown that both b-
arrestins promote NF-kB activation following the activation GPCRs
[23,24]. The roles of b-arrestins on C3a-induced NF-kBa c t i v a t i o na n d
chemokine production in mast cells have not been determined.
The mitogen-activated protein kinases (MAPKs), extracellular
signal-regulated kinases 1 and 2 (ERK1/2) play important roles in
a variety of cellular responses and have been studied for a variety
of GPCRs. Activation of GPCRs in transfected cell lines induce
ERK1/2 phosphorylation via two temporally distinct pathways;
an early response that reflects G protein activation and an delayed
response that is G protein independent but requires the formation
of signaling complexes involving Src/ERK with b-arrestin [25,26].
Although C3a induces ERK1/2 phosphorylation in mast cells
[7,9,27], whether or not b-arrestin-1 and b-arrestin-2 regulate this
response remains unknown.
The goal of the present study was to determine the roles of b-
arrestins on the regulation of C3aR signaling in human mast cells.
To achieve this goal, we utilized lentivirus shRNA to stably
knockdown the expression of b-arrestin-1 and b-arrestin-2 in
human mast cells (HMC-1 and LAD2). Using these systems, we
report unexpected findings regarding distinct roles of these adapter
molecules on C3aR desensitization, internalization, degranulation,
NF-kB activation and chemokine generation. Furthermore, we
provide first demonstration that both b-arrestins acts as novel
inhibitors of C3a-induced G-protein-mediated ERK1/2 phos-
phorylation in human mast cells.
Results
Stable knockdown of b-arrestin-1 and b-arrestin-2 in a
human mast cell, HMC-1
To determine the role of b-arrestins on the regulation of C3aR
signalingin mast cells, we used the Mission shRNA lentivirus system
to stably knockdown the expression of b-arrestin-1 and b-arrestin-2
in a human mast cell line; HMC-1 cells. Cells were transduced with
5 different shRNA constructs targeting different regions of b-
arrestin-1 and b-arrestin-2. For control, we used a scrambled
shRNA construct. After transduction and selection with puromycin,
quantitative real-time PCR was performed to determine the extent
of b-arrestin knockdown. As shown in Fig. 1A and B, all five b-
arrestin shRNA constructs decreased the expression of b-arrestin-1
and b-arrestin-2 to variable levels. Clone 3 (TRCN0000230149) for
b-arrestin-1 and clone 5 (TRCN0000159482) for b-arrestin-2
showed .80% decrease in mRNA. We therefore, used these clones
to generate double knockdown (both b-arrestin-1 and b-arrestin-2)
in HMC-1 cells. As shown in Fig. 1C, we were able to generate
Figure 1. Stable knockdown of b-arrestin-1 and b-arrestin-2 in human mast cells. HMC-1 cells were stably transduced with scrambled
shRNA control lentivirus or different clones of shRNA lentivirus targeted against b-arrestin-1 and b-arrestin -2 (Panels A and B). For double knockdown
HMC-1 cell were transduced with shRNA lentivirus, Clone 3 of b-arrestin-1 and Clone 5 of b-arrestin-2 (C). Quantitative PCR was employed to assess b-
arrestin-1 or -2 mRNA levels. Results are expressed as a ratio of b-arrestin to GAPDH mRNA levels. Data represent the mean 6 SEM from three
independent experiments. Statistical significance was determined by one way ANOVA. ** indicates p,0.001.
doi:10.1371/journal.pone.0019585.g001
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were used in subsequent studies described below.
b-arrestin-2, but not b-arrestin-1, is required for C3aR
desensitization and internalization
Intracellular Ca
2+ mobilization provides a rapid, sensitive and
real-time assay to measure receptor desensitization [28]. We have
previously shown that receptors that undergo desensitization
respond to agonists with an initial Ca
2+ spike, which decays rapidly
and reaches baseline within ,2–3 min [28]. By contrast, phos-
phorylation-deficient receptors that do not associate with b-arrestin
respond to agonist for a similar initial Ca
2+ spike, followed by a
sustained response that remains elevated for an extended period of
time [29,30]. We therefore, used Ca
2+ mobilization as an assay to
determine the effects of b-arrestin-1 and b-arrestin-2 knockdowns
on C3aR desensitization. As shown in Fig. 2A and B, C3a caused a
rapid increase in Ca
2+ mobilization in shRNA control and b-
arrestin-1 knockdown cells. By contrast, in b-arrestin-2 knockdown
C3a caused a similar initial spike but subsequent response was
sustained (Fig. 2C). Furthermore, deletion of both b-arrestins
resulted in a Ca
2+ response similar to that observed in b-arrestin-2
knockdown cells (Fig. 2C and D). These findings suggest that b-
arrestin-2, but not b-arrestin-1, mediates desensitization of C3aR.
GPCRs that undergo desensitization display reduced responsive-
ness to a second stimulation with the same agonist [28]. To test
further the effects of b-arrestins on desensitization, shRNA control or
knockdown cells were exposed to C3a and washed twice before re-
exposure to the same concentration of C3a. In shRNA control and b-
arrestin-1 knockdown cells, there was little or no response to second
C3a stimulation. Interestingly, b-arrestin-2 knockdown cells respond-
ed to re-exposure to C3a for Ca
2+ mobilization (Fig. 2C). Notably,for
initial Ca
2+ mobilization and desensitization, double knockdown cells
responded similarly to b-arrestin-2 knockdown cells (Fig. 2D).
To investigate the role of b-arrestins on agonist-induced C3aR
internalization, shRNA control, b-arrestin-1 and b-arrestin-2
knockdown cells were exposed to buffer or C3a and receptor
Figure 2. Knockdown of b-arrestin-2, but not b-arrestin-1, attenuates C3aR desensitization. (A), shRNA control, (B) b-arrestin-1 KD
(knockdown), (C) b-arrestin-2 KD and (D) double b-arrestin-1 and 2 KD cells were loaded with Indo-1(1 mM), stimulated with C3a (100 nM) for 5 min
and intracellular Ca
+2 mobilization was determined (black solid lines). The cells were immediately washed three times with ice-cold buffer,
resuspended in warm buffer and exposed to a second stimulation of C3a (100 nM) and intracellular Ca
2+ mobilization was again determined (red
broken lines). Data shown are representative of three similar experiments.
doi:10.1371/journal.pone.0019585.g002
C3a Receptor Regulation by b-arrestin in Mast Cells
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19585internalization was determined by flow cytometry. In shRNA
control cells, C3a caused a robust internalization of its receptors
(Fig. 3A). In b-arrestin-1 knockdown cells, there was no marked
difference in the extent of receptor internalization (Fig. 3A, B).
Interestingly, internalization of C3aR was substantially reduced in
b-arrestin-2 knockdown cells (Fig. 3C and D). These findings
clearly demonstrate that b-arrestin-2, but not b-arrestin-1, is
involved in C3aR desensitization and internalization in human
mast cell line, HMC-1.
b-arrestin-1, but not b-arrestin-2, promotes C3a-induced
mast cell degranulation
Our next goal was to determine the roles of b-arrestin-1 and b-
arrestin-2 on C3a-induced mast cell degranulation. We could not
use HMC-1 cells for these studies because this immature mast cell
line has little or no capacity to degranulate. LAD2 mast cells
express C3aR and responds to ligand for Ca
2+ mobilization and
degranulation [7]. We therefore knocked down the expression of
b-arrestin-1 and b-arrestin-2 in LAD2 cells. As in HMC-1 cells,
lentiviral shRNA induced ,80% knockdown of the b-arrestin-1
and b-arrestin-2 in LAD2 mast cells (Fig. 4A). Furthermore,
consistent with the findings in HMC-1 cells, b-arrestin-1
knockdown in LAD2 cells had little or no effect on C3a-induced
Ca
2+ mobilization (Fig. 4B and C) while b-arrestin-2 silencing
resulted in a more sustained Ca
2+ mobilization and loss of
desensitization (Fig. 4D). Surprisingly, however, knockdown of b-
arrestin-2 had no effect on C3a-induced mast cell degranulation
but the absence of b-arrestin-1 resulted in a significantly decreased
degranulation response (Fig. 4E).
b-arrestin-2, but not b-arrestin-1, inhibits C3a-induced
NF-kB activation and chemokine CCL4 generation
b-arrestin-1 and b-arrestin-2 bind to IkBa to inhibit GPCR-
induced NF-kB activity in transfected cell lines [19,20]. We
therefore sought to determine the roles of these adapter molecules
on C3a-induced NF-kB luciferase activity in human mast cells. We
used HMC-1 cells for these studies because they are more
amenable to transfection than LAD2 cells. C3a did not induce NF-
Figure 3. Knockdown of b-arrestin-2, but not b-arrestin-1, inhibits agonist-induced C3aR internalization. (A) shRNA control HMC-1 cells
(B) b-arrestin-1 KD and (C) b-arrestin-2 KD cells were exposed to buffer (2C3a) or C3a (100 nM) for 5 min. Cells were washed with ice-cold FACS
buffer, incubated with a mouse anti-C3aR antibody or an isotype control antibody followed by PE-labeled donkey anti-mouse IgG antibody and
analyzed by flow cytometry. Representative histograms showing cell surface C3aR expression in (A) shRNA control, (B) b-arrestin-1 KD and (C) b-
arrestin-2 KD cells are shown. (D) shRNA control, b-arrestin-1 KD and b-arrestin-2 KD cells were exposed to C3a for different time periods and receptor
internalization was determined as described above. Internalization is expressed as the percentage loss of C3aR following exposure to C3a. Data
represent the mean 6 SEM from three experiments. Statistical significance was determined by two way ANOVA with Bonferroni’s post test.
* indicates p,0.05.
doi:10.1371/journal.pone.0019585.g003
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HMC-1 cells (Fig. 5A). By contrast, b-arrestin-2 knockdown cells
showed a significant enhancement in C3a-induced NF-kB
luciferase activity as compared to shRNA control cells. Given
that NF-kB plays an important role in the generation of
proinflammatory cytokines, we tested the effects of b-arrestin-1
and b-arrestin-2 knockdown in C3a-induced chemokine CCL4
production. Consistent with NF-kB activation, C3a induced
CCL4 only in b-arrestin-2 silenced cells (Fig. 5B).
b-arrestin-1 and b-arrestin-2 inhibit C3a-induced ERK1/2
phosphorylation
Activation of GPCRs leads to ERK1/2 phosphorylation via two
temporally distinct pathways; an early response that reflects G
protein activation and a delayed response that is G protein
independent but requires b-arrestins [31]. We therefore investi-
gated the effects of silencing the expression of b-arrestin-1, b-
arrestin-2 or both on the time course of C3a-induced ERK1/2
phosphorylation in HMC-1 cells. In shRNA control cells, C3a
caused a transient ERK1/2 phosphorylation that peaked between
1–5 min and returned to basal thereafter (Fig. 6A). Surprisingly,
silencing b-arrestin-1 or b-arrestin-2 expression enhanced the
magnitude of this early response and rendered the cells responsive
to C3a for ERK1/2 phosphorylation even at later time points (10–
30 min). Furthermore, in double knockdown cells, C3a-induced
ERK1/2 phosphorylation was greater in magnitude than single b-
arrestin knockdown cells (Fig 6A and 6B).
To determine if the delayed C3a-induced ERK1/2 phosphory-
lation in b-arrestin knockdown cells is mediated via a G protein-
dependent pathway,shRNAcontrol andb-arrestin-1and b-arrestin-
2 double knockdown cells were exposed to pertussis toxin and the
effects of C3a on ERK1/2 phosphorylation was determined. As
shown in Fig. 7A and 7B both early and delayed responses were
almost completely inhibited in pertussis toxin treated cells.
Discussion
b-arrestins are well known for their roles in GPCR desensiti-
zation and internalization. They also modulate downstream
signaling pathways such as those for ERK and NF-kB indepen-
Figure 4. Knockdown of b-arrestin-1, but not b-arrestin-2, inhibits C3a-induced degranulation in LAD2 mast cells. (A) LAD2 cells were
transduced with shRNA control, b-arrestin-1, and b-arrestin-2 lentivirus. After puromycin selection, quantitative PCR was employed to assess the b-
arrestin-1 or b-arrestin-2 mRNA level and results are expressed as a ratio of b-arrestin to GAPDH mRNA levels. (B, C, D) A representative desensitization
experiment in shRNA control, b-arrestin-1 and b-arrestin-2 knockdown LAD2 cells is shown. (E) shRNA control, b-arrestin-1 and -2 KD LAD2 mast cells
were stimulated with different concentrations of C3a and percent degranulation (b-hexosaminidase release) was determined. Data represent the
mean 6 SEM from three independent experiments. Statistical significance was determined by two way ANOVA with Bonferroni’s post test. * indicates
p,0.05 and ** indicates p,0.001.
doi:10.1371/journal.pone.0019585.g004
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regulation have been performed using mouse embryonic fibro-
blasts (MEFs) derived from b-arrestin null mice [11], transfected
cell lines overexpressing b-arrestins or siRNA-mediated b-arrestin
knockdown in HEK293 cells [32,33,34,35]. For the present study,
we utilized lentivirus shRNA to stably knockdown the expression
of b-arrestin-1 and b-arrestin-2 in human mast cell lines, HMC-1
cells and LAD2 cells that endogenously express C3aR. Using this
approach, we have uncovered distinct roles of b-arrestin-1 and b-
arrestin-2 on C3aR desensitization, internalization, degranulation,
NF-kB activation and chemokine generation. Furthermore, we
provided the first demonstration that b-arrestin-1 and b-arrestin-2
act as novel inhibitors of C3a-induced G protein-dependent
ERK1/2 phosphorylation in human mast cells.
Previous studies indicated that b-arrestin-2 either inhibits or
promotes chemoattractant/chemokine induced degranulation.
Thus, in response to agonist stimulation wild-type chemoattractant
receptors associate with b-arrestin-2 in transfected RBL-2H3 cells
but phosphorylation-deficient mutants do not [9,14,16,30].
Furthermore, agonist-induced Ca
2+ mobilization and degranula-
tion are enhanced in cells expressing phosphorylation-deficient
receptors when compared to wild-type receptors. These findings
are consistent with the notion that receptor phosphorylation and
b-arrestin-2 participate in receptor desensitization. By contrast,
Barlic et al., [17] showed that agonist induced phosphorylation of
the chemokine receptor CXCR1 leads to b-arrestin-2-mediated
receptor internalization and the formation of b-arrestin-2-Hck
complex, which migrates to secretory granules initiating the
process of degranulation. The finding in the present study that
enhanced Ca
2+ response in the absence of b-arrestin-2 did not
promote greater degranulation provides a possible explanation for
the previously published conflicting data for the role of b-arrestin-
2 on degranulation. It suggests that b-arrestin-2 plays a dual role
on GPCR-induced degranulation; inhibition via desensitization
and activation via its association with Hck. Thus, the inability of
enhanced Ca
2+ response to promote greater degranulation in b-
arrestin-2 knockdown cells probably reflects the loss of b-arrestin-
2-mediated Hck signaling (see Model in Fig. 8A).
An interesting finding of the present study was that while
knockdown of b-arrestin-1 had no effect on C3aR desensitization
(as measured by Ca
2+ mobilization) or receptor internalization its
absence resulted in a substantial inhibition of C3a-induced mast
cell degranulation. Because b-arrestins 1 does not participate in
C3aR internalization, C3a is unlikely to promote Hck-b-arrestin-1
interaction. Our studies with confocal microscopy in live cells
indicated that C3a causes translocation of b-arrestin-1 to the
plasma membrane (data not shown). Furthermore, b-arrestin 1
forms a complex with Ral-GDS in the cytoplasm of human
neutrophils [18]. This raises the interesting possibility that upon
C3aR activation, b-arrestin-1/Ral GDS complex translocates to
the plasma membrane to promote degranulation and that
knockdown of b-arrestin-1 leads to attenuated response due to
the absence of this complex (see Model in Fig. 8A). Whether this or
other mechanism(s) participate on the effect of b-arrestin-1 on
C3a-induced mast cell degranulation remains to be determined.
b-arrestins have beenshown to promote or inhibit NF-kB activity
depending on the cell type and receptors utilized [14,19,20,23,24].
Our results clearlydemonstratethat b-arrestin-2, butnot b-arrestin-
1, inhibits C3a-induced NF-kB activation and chemokine genera-
tion. Gao et al., [20] recently observed similar differences between
b-arrestin-1 and b-arrestin-2 in cytokine production in Hela cells
and THP-1 monocytes. This difference was thought to reflect a
reduced ability of b-arrestin-1 to form a complex with the inhibitory
IkBa when compared to b-arrestin-2. In the present study, we
showed that while b-arrestin-1 does not participate in agonist-
induced C3aR internalization, b-arrestin-2 is essential for this
response. It is therefore possible that internalized C3aR-b-arrestin-2
complex interacts with IkBa to keep NF-kB inactive and that
depletion of b-arrestin-2 removes this inhibitory constraint to allow
NF-kB activation and chemokine generation (Fig. 8B). It is also
Figure 5. Knockdown of b-arrestin-2, but not b-arrestin-1, enhanced C3a-induced NF-kB activation and chemokine CCL4
generation. shRNA control, b-arrestin-1 KD or b-arrestin-2 KD HMC-1 cells were transiently transfected with NF-kB luciferase reporter gene
construct. (A) Cells were stimulated with C3a (100 nM for 6 hr) and NF-kB-dependent transcriptional activity was determined by luciferase activity
assay. (B) Control or b-arrestin KD cells were stimulated with C3a (100 nM for 6 hr) and CCL4 production was determined from the supernatant by
ELISA. Data shown are mean 6 SEM of three experiments performed in triplicate. Statistical significance was determined by two way ANOVA with
Bonferroni’s post test. ** indicates p,0.001.
doi:10.1371/journal.pone.0019585.g005
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Ca
2+ mobilization in b-arrestin-2 knockdown cells results in greater
NF-kB activation and chemokine generation.
An interesting finding of the present study was that silencing b-
arrestin-1 and b-arrestin-2 enhanced early ERK1/2 phosphorylation
in response to C3a and also rendered the cellsresponsive to C3a at later
time points (15–30 min). This finding is in direct contrast to situations
with many other GPCRs, where b-arrestins are required for delayed
ERK phosphorylation [31]. One possible interpretation of our finding
is that knockdown b-arrestins attenuate C3aR desensitization leading
to more sustained ERK1/2 phosphorylation. This explanation is,
however, unlikely as b-arrestin-1 knockdown, which had no impact on
C3aR desensitization, rendered the cells responsive to C3a for ERK1/
2 phosphorylation. Ahn et al. [33] recently demonstrated that b-
arrestin-2 inhibits angiotensin II type 1A-mediated ERK1/2 activation
in HEK293 cells and silencing b-arrestin-1 expression enhances this
response by blocking b-arrestin-2 mediated inhibition. This type of
reciprocal regulation is unlikely for C3a-induced response in mast cells
as knockdown of both b-arrestins either individually or together
enhanced C3a-induced ERK1/2 phosphorylation.
It is noteworthy that Drosophila genome encodes a single b-arrestin,
Kurtz (Krz), which controls olfaction, behavior, sensitivity to osmotic
stress, and is essential for survival of the fly [36,37,38]. Tipping et al.,
[39] recently showed that Krz directly binds to and sequesters an
inactive form of ERK, thus preventing its activation by the upstream
kinase, MEK. We have shown that pertussis toxin completely blocks
the transient C3a-induced ERK1/2 phosphorylation in shRNA
control cells as well as the sustained response in b-arrestin-1 and b-
arrestin-2 double knockdown cells. This finding suggests that C3a
causes ERK1/2 phosphorylation via a GPCR-mediated pathway
and that arrestins inhibit this response by forming a direct complex
with ERK and preventing it activation by MEK (Fig. 8B).
In summary, we demonstrated distinct roles for b-arrestins-1
and b-arrestins-2 on C3aR desensitization, internalization,
degranulation, NF-kB activation and chemokine generation in
human mast cells. Most importantly, we provided the first
demonstration that both b-arrestin-1 and b-arrestin-2 act as novel
inhibitors of C3a-induced G-protein-mediated ERK1/2 phos-
phorylation in human mast cells. In addition to C3aR, human
mast cells express a large number of other GPCRs, FceRI, toll-like
Figure 6. C3a-induced ERK1/2 phosphorylation is enhanced in b-arrestin-1, b-arrestin-2 and double KD cells. shRNA control or b-
arrestin KD HMC-1 cells (1610
6/ml) were exposed to C3a (100 nM) for 1, 5 and 10, 15 and 30 min. Cell lysates were separated on SDS-PAGE and blots
were probed with anti-phospho-ERK1/2 antibody followed by anti-rabbit IgG-HRP. The blots were then stripped and reprobed with anti-ERK1/2
antibody followed by anti-rabbit IgG-HRP. Immunoreactive band were visualized by SuperSignal West Femto maximum sensitivity substrate. (A)
Representative immunoblots from three similar experiments are shown. (B) ERK1/2 phosphorylation was quantified using Image J as shown in the
line graph. Data represent the mean 6 SEM from three independent experiments. Statistical significance was determined by two way ANOVA with
Bonferroni’s post test. ** indicates p,0.001.
doi:10.1371/journal.pone.0019585.g006
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that b-arrestins regulate GPCR and non-GPCR signaling [45,46],
it is likely that they regulate other receptor/signaling pathways in
human mast cells. Our future studies will focus on the receptor
specificity of human mast cell regulation by b-arrestins.
Materials and Methods
Materials
Mission shRNA bacterial glycerol stocks for b-arrestins were
purchased from Sigma Life Sciences (St. Louis, MO). Indo-1 AM
was from Molecular Probes (Eugene, OR). All tissue culture
reagentswerepurchasedfromInvitrogen(Gaithersburg,MD).Anti-
human C3aR was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA), PE-labeled donkey anti-mouse IgG was purchased from
eBioscience (San Diego, CA). All recombinant human cytokines
were purchased from Peprotech (Rocky Hill, NJ). Rabbit anti-
ERK1 and anti-phospho-ERK1/2 antibodies were purchased from
Cell Signaling (Beverly, MA). SuperSignalH West Femto Maximum
Sensitivity Substrate and HRP labeled Goat anti-rabbit IgG were
from Thermo Scientific (Rockford, IL). Purified C3a was obtained
from Advanced Research Technologies (San Diego, CA). CCL4
ELISA kit was purchased from R&D Systems (Minneapolis, MN).
Mast cell culture
HMC-1 cells were cultured in Iscove’s modified Dulbecco’s
medium (IMDM) supplemented with 10% FCS, glutamine
(2 mM), penicillin (100 IU/mL) and streptomycin (100 mg/mL)
[47]. LAD2 cells were maintained in complete StemPro-34
medium supplemented with 100 ng/mL rhSCF [48].
Lentivirus and stable transduction of shRNAs in mast
cells
The following b-arrestin-1 and -2 targeted shRNAs in Lentiviral
construct plasmid were purchased from Sigma-Aldrich (St.
Louis, MO): b-arrestin-1 (NM_004041) Clone 1 TRCN000023-
0148, Clone 2 TRCN0000230147, Clone 3 TRCN0000230149,
Figure 7. Enhanced C3a-induced ERK1/2 phosphorylation in b-arrestin KD cells mast is mediated via a G protein-dependent
pathway. shRNA control and double b-arrestin KD cells were pretreated with vehicle or Pertussis toxin (PTx; 100 ng/ml, 16 hr). Cell were then
washed twice in serum free medium and stimulated with C3a (100 nM) for 1, 5 and 10, 15 and 30 min and ERK1/2 phosphorylation were determined.
(A) Representative immunoblots from three similar experiments are shown. (B). ERK1/2 phosphorylation was quantified using Image J as shown in the
bar graph. Data represent the mean 6 SEM from three independent experiments. Statistical significance was determined by two way ANOVA with
Bonferroni’s post test. ** indicates p,0.001.
doi:10.1371/journal.pone.0019585.g007
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arrestin-2 (NM_004313) Clone 1 TRCN0000165387, Clone 2
TRCN0000164794, Clone 3 TRCN0000159332, Clone 4
TRCN0000161834, Clone 5 TRCN0000159482 and control
non-target vector SHC002. Cell transduction was conducted by
mixing 1.5 ml of virus with 3.5 ml of HMC-1 or LAD-2 cells
(5610
6). For the double knockdown of b-arrestin-1 and -2, 1.5 ml
of each virus of specific clones were transduced in 2 ml of HMC-1
or LAD-2 cells (5610
6). Eight hr post-infection, medium was
changed to virus-free complete medium, and antibiotic (puromy-
cin; 2 mg/ml Sigma-Aldrich) selection was initiated 16 h later.
Cells were analyzed for b-arrestin knockdown one week after
initiation of puromycin selection.
Real-Time PCR
Total RNA was extracted from 4610
6 of cells using TRIZOL,
treated with DNase I and subsequently purified for genomic DNA
contamination with RNeasy mini Kit (Qiagen) according to the
manufacture’s instruction. cDNA was synthesized from genomic
DNA-free RNA using the cDNA synthesis kit from GE
Healthcare. Gene expression was analyzed using real time PCR
with TaqmanH Fast Universal PCR Master Mix on a Taqman
7500 Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA). Taqman hGAPDH, b-arrestin-1 and b-arrestin-2
primers were used for real time PCR to analyze the knockdown
efficiency. The amplification conditions were as follows: initial
denaturation at 95uC for 20 sec, followed by 40 cycles of
amplification: 95uC for 3 sec, 60uC for 30 sec. Analysis was
performed according to DD-Ct method. The results were
expressed as b-arrestin-1 or -2/GAPDH ratio.
C3a Receptor desensitization
Receptor desensitization assay based on Ca
2+ mobilization was
determined as described previously [49]. Briefly, 1610
6 HMC-1
or 0.25610
6 LAD-2 cells were washed twice with buffer (119 mM
NaCl, 5 mM KCl, 25 mM HEPES, 5.6 mM Glucose, 0.4 mM
MgCl2, 1 mM CaCl2) containing 1 mg/ml BSA and incubated
with 1 mM of Indo-1 for 30 min in dark. Cells were then washed
and resuspended in 1.5 ml of the same buffer and time course of
Ca
2+ mobilization (0–5 min) was determined using Hitachi F-2500
Fluoro spectrophotometer (San Jose, CA) with an excitation
wavelength of 355 nM and an emission wavelength of 410 nM
[9]. For desensitization assay, cells were removed from the cuvette,
washed twice and Ca
2+ mobilization to a subsequent exposure of
C3a (100 nM) was determined.
Degranulation Assay
LAD-2 cells (1.2610
4) were seeded into 96-well plates in a total
volume of 50 ml of buffer containing 1 mg/ml BSA and exposed to
different concentrations of C3a (1, 10 and 100 nM). For total b-
hexosaminidase release, control cells were lysed in 50 ml of 0.1%
Triton X-100. Aliquots (20 ml) of supernatants or cell lysates were
incubated with 20 ml of 1 mM p-nitrophenyl-N-acetyl-b-D-
glucosamine for 1.5 hour at 37uC. The reaction was stopped by
adding 250 ml of a 0.1 M Na2CO3/0.1 M NaHCO3 buffer and
absorbance measured at 405 nm [49].
Receptor Internalization
ShRNA control and b-arrestin knockdown HMC-1 cells
(2.5610
5) were stimulated with or without C3a (100 nM) at
37uC. Cells were washed twice and resuspended in 50 ml of ice-
cold FACS buffer (PBS containing 2% FBS). C3aR antibody or
isotype control (2 ml) was added and the cells were incubated on
ice for 1 h. Cells were washed twice and re-suspended in 48.5 mlo f
ice-cold FACS buffer. Phycoerythrin (PE)-labeled donkey anti-
mouse (1.5 ml) was added and incubated on ice for 1 h. Cells were
washed twice with cold FACS buffer and fixed in 250 mlo f2 %
formaldehyde. Receptor internalization was quantified as the loss
Figure 8. Model for the Regulation of C3aR signaling in human mast cells by b-arrestin-1 and b-arrestin-2. (A): b-arrestin-2 causes
desensitization and internalization of C3aR but both b-arrestins promote G protein-independent signaling for degranulation via the activation of Hck
and/or Ral-GDS-mediated signaling pathways [17,18]. (B) b-arrestin-2 mediates inhibition of C3a-induced NF-kB activity but both b-arrestins block
C3a-induced G-protein-mediated ERK1/2 phosphorylation. Red dotted lines denote inhibition.
doi:10.1371/journal.pone.0019585.g008
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cytometer (BD Biosciences).
ERK1/2 Phosphorylation
ShRNA control and b-arrestin knockdown HMC-1 cells were
serum starved overnight. The following day, cells were washed
twice and resuspended in serum free IMDM medium at a
concentration of 1610
6/ml and stimulated C3a (100 nM ) for
different time points. Three-fold volume of ice-cold PBS
containing 1 mM sodium orthovanadate was added to stop the
reaction. Total cell lysate was prepared with RIPA buffer
(150 mM NaCl, 1.0% NP-40, 0.5% Sodium-deoxycholate,
0.10% SDS, 50 mM Tris [pH 8.0], 5 mM EDTA, 10 mM NaF,
10 mM Na-pyrophosphate and protease inhibitor cocktail) and
subsequently analyzed by Western blot using rabbit polyclonal
antibodies for phospho-p44/42 MAPK (pERK1/2) and p44/42
MAPK (ERK1/2).
NF-kB luciferase reporter activity
ShRNA control and b-arrestin knockdown HMC-1 cells
(3610
6) were seeded in 12-well plates. The following day, cells
were co-transfected with NF-kB luciferase reporter gene construct
(pNF-kB-LUC and p-Renilla Stratagene, Santaclara, CA) (in a
10:1 ratio) using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) in serum-free IMDM medium as per manufacturer
protocol. Six hour post-transfection, medium was replaced with
IMDM containing 10% FBS. After 18 hr of incubation in
complete medium, cells were re-plated and stimulated in the
presence or absence of 100 nM C3a for 6 hr. Cells were then
harvested, washed in ice-cold PBS and finally lysed in Promega
passive lysis buffer (Dual Luciferase assay kit; Promega, Madison,
WI). NF-kB luciferase activity was measured using Turner
biosystem 20/20 Luminometer (Promega, Madison, WI). Results
expressed have been normalized to Renilla.
CCL4 chemokine release assay
Chemokine release assay was performed as previously described
[27]. HMC-1 shRNA control, b-arrestin-1 and b-arrestin-2
knockdown cells (0.2610
6 cells) were stimulated with 100 nM
C3a for 6 hours. CCL4 chemokine levels were quantified by
sandwich ELISA according to the manufacturer’s protocol.
Data analysis
The results are expressed as 6 S.E.M for the values obtained
from experiment. GraphPad Prism software (Graph Pad, Version
5.0 San Diego, CA) was used to analyze data for statistical
significance. The statistical significance was determined by one-
way analysis of variance (ANOVA) with Dunnett’s multiple
comparison post hoc test, and two way ANOVA with Bonferroni’s
post test.
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